13956-29-1

Chemistry informtion about Cannabidiol (CAS NO.13956-29-1) is:
IUPAC Name: 2-[(6r)-3-Methyl-6-Prop-1-En-2-Ylcyclohex-2-En-1-Yl]-5-Pentylbenzene-1,3-Diol
Synonyms: (-)-Trans-2-P-Mentha-1,8-Dien-3-Yl-5-Pentylresorcinol ; (-)-Trans-Cannabidiol ; ,(1r-Trans)- ; 1,3-Benzenediol, 2-[3-Methyl-6-(1-Methylethenyl)-3-Cyclohexen-1-Yl]-5-Pentyl- ; 2-(3-Methyl-6-(1-Methylethenyl)-2-Cyclohexen-1-Yl)-5-Pentyl-3-Benzenediol ; 2-(6-Isopropenyl-3-Methyl-2-Cyclohexen-1-Yl)-5-Pentyl-1,3-Benzenediol ; 8-Dien-3-Yl-5-Pentyl-2-P-Mentha-(-)-(E)-Resorcino ; Delta1(2)-Trans-Cannabidiol
Product Categories: Cannabinoid receptor 
MF: C₂₁H₃₀O₂
MW: 314.46 
Density: 1.025 g/cm³
Flash Point: 206.3 °C
Boiling Point: 463.9 °C at 760 mmHg
Vapour Pressure: 3.14E-09 mmHg at 25°C 
Enthalpy of Vaporization: 75.31 kJ/mol
Storage temp.: 2-8°C
Following is the molecular structure of Cannabidiol (CAS NO.13956-29-1) is:

 

In April 2005, Canadian authorities approved the marketing of Sativex, a mouth spray for multiple sclerosis to alleviate pain. Sativex contains tetrahydrocannabinol together with Cannabidiol (CAS NO.13956-29-1). Initial research is showing that CBD has an effect in reducing schizophrenic symptoms in patients. Further research has verified these results. Leweke et al., (2009) performed a double blind, 4 week, explorative study controlled clinical trial, to compare the effects of purified cannabidiol and the atypical antipsychotic amisulpride on improving the symptoms of schizophrenia in 42 patients with acute schizophrenia. 'Both treatments were associated with a significant decrease of psychotic symptoms after 2 and 4 weeks as assessed by BPRS and PANSS. However, there was no statistical difference between both treatment groups. In contrast, cannabidiol induced significantly less side effects (EPS, increase in prolactin, weight gain) when compared to amisulpride'. The authors conclude cannabidiol revealed substantial antipsychotic properties in acute paranoid schizophirenia (Leweke et al., 2009). This led the authors to suggest the endocannabinoid system plays an adaptive role in the development of paranoid schizophirenia and that this research provides evidence that this mechanism may be a valuable target for 'antipsychotic treament strategies' .

EPA Genetic Toxicology Program.

Poison by intravenous route. An experimental teratogen. Other experimental reproductive effects. Mutation data reported. When heated to decomposition it emits acrid smoke and fumes.
Hazard Codes:
F
T
Risk Statements:
R11:Highly flammable. 
R23/24/25:Toxic by inhalation, in contact with skin and if swallowed. 
R39/23/24/25:Toxic by inhalation, in contact with skin and if swallowed and danger of very serious irreversible effects.
Safety Statements:
S36/37:Wear suitable protective clothing and gloves. 
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) 
S16:Keep away from sources of ignition. 
S7:Keep container tightly closed.
RIDADR: UN 1230 3/PG 2
WGK Germany: 1
RTECS: VH1600000

Cannabidiol (CAS NO.13956-29-1) is a psychoactive cannabinoid found in Cannabis. It is a major constituent of the plant, representing up to 40% in its extracts.It is not intoxicating but displayed sedative effects in animal tests. Some research, however, indicates that CBD can increase alertness. It may decrease the rate of THC clearance from the body, perhaps by interfering with the metabolism of THC in the liver. CBD appears to affect both the CB1 and CB2 receptors- with higher affinity for the CB2 receptors . Cannabis indica dominant strains of the plant are known to be higher in CBD than Cannabis sativa strains. Medically, it appears to relieve convulsion, inflammation, anxiety, and nausea, and to inhibit cancer cell growth. Recent studies have shown cannabidiol to be as effective as atypical antipsychotics in treating schizophrenia.